Rituximab News and Research

RSS
Rituximab is approved by the Food and Drug Administration (FDA) to be used alone or with other drugs to treat certain types of B-cell non-Hodgkin lymphoma. It is also approved to be used with methotrexate to treat rheumatoid arthritis. Rituximab is also being studied in the treatment of other types of cancer and other conditions.
Turning autoimmunity drugs into anti-cancer treatments

Turning autoimmunity drugs into anti-cancer treatments

Novel compound shows promise for ANCA-associated vasculitis

Novel compound shows promise for ANCA-associated vasculitis

Phase III clinical trial shows benefit of rituximab for pediatric Burkitt lymphoma

Phase III clinical trial shows benefit of rituximab for pediatric Burkitt lymphoma

Study focuses on COVID-19 patients with inflammatory rheumatic diseases

Study focuses on COVID-19 patients with inflammatory rheumatic diseases

Drug combo for untreated CLL approved by FDA based on E1912 trial

Drug combo for untreated CLL approved by FDA based on E1912 trial

Novel and targeted cellular product causes cell death in non-Hodgkin lymphoma models

Novel and targeted cellular product causes cell death in non-Hodgkin lymphoma models

Ibrutinib-based therapy provides superior clinical outcomes in majority of CLL patients

Ibrutinib-based therapy provides superior clinical outcomes in majority of CLL patients

Study: Calcium signaling can help address drug resistance to non-Hodgkin lymphoma

Study: Calcium signaling can help address drug resistance to non-Hodgkin lymphoma

Tailored T-cells safe, may be effective in preventing and treating multiple viral infections

Tailored T-cells safe, may be effective in preventing and treating multiple viral infections

Drug regimen for lymphoma and RA more likely to put patients with pemphigus into remission

Drug regimen for lymphoma and RA more likely to put patients with pemphigus into remission

Juvenile immune arthritis – new treatments wanted

Juvenile immune arthritis – new treatments wanted

Tocilizumab more effective than rituximab in achieving low disease activity in RA patients

Tocilizumab more effective than rituximab in achieving low disease activity in RA patients

Study provides first data on infectious risk in children exposed to non-TNFi biologics and tofacitinib

Study provides first data on infectious risk in children exposed to non-TNFi biologics and tofacitinib

Additional medications needed to control the symptoms of juvenile idiopathic arthritis

Additional medications needed to control the symptoms of juvenile idiopathic arthritis

New research shows significant gaps in deployment of 'coverage with evidence development'

New research shows significant gaps in deployment of 'coverage with evidence development'

First chemoimmunotherapy regimen approved by FDA for patients with diffuse large B-cell lymphoma

First chemoimmunotherapy regimen approved by FDA for patients with diffuse large B-cell lymphoma

Study reveals investigational drug as effective treatment for relapsed marginal zone lymphoma

Study reveals investigational drug as effective treatment for relapsed marginal zone lymphoma

Researchers find cause, treatment for CVID lung disease using precision medicine

Researchers find cause, treatment for CVID lung disease using precision medicine

First biosimilar approved by FDA for treatment of adult patients with non-Hodgkin’s lymphoma

First biosimilar approved by FDA for treatment of adult patients with non-Hodgkin’s lymphoma

Phase III CLL14 study evaluating Venclexta plus Gazyva to treat CLL meets its primary endpoint

Phase III CLL14 study evaluating Venclexta plus Gazyva to treat CLL meets its primary endpoint